Antipsychotic Drugs and Their Side-Effects

by Thomas R.E. Barnes (Editor), Peter Jenner (Editor)

Overview

In line with other volumes in the Neuroscience Perspectives Series, this volume covers the background, pharmacology, molecular biology, and biochemistry of antipsychotic drugs, together with an overview assessment of the therapeutic considerations. Over the past 40 years, the effectiveness of conventional neuroleptic agents for psychotic illness has been offset by a wide range of adverse side-effects, including motor side-effects like parkinsonism. Studies show that lowering doses may still produce the antipsychotic effect while lessening the risk of side-effects. As all available antispychotic drugs are able to block dopamine, specifically D2 receptors, doses below the threshold level for producing acute motor disorder can still be therapeutically effective. With the identification and characterization of multiple dopamine receptors, the possibility of more selective drugs with better side-effect potential has arisen. Other novel antipsychotic agents include D1 receptor blockers, partial dopamine agonists and non-dopamine drugs such as 5-HT receptor blockers, sigma receptor antagonists and NMDA receptor agonists. This volume reviews both the basic science of the conventional and atypical neuroleptics and their present and potential therapeutic use.

Product Details

ISBN-13:	9781483288109
Publisher:	Elsevier Science
Publication date:	10/22/2013
Series:	ISSN
Sold by:	Barnes & Noble
Format:	eBook
Pages:	287
File size:	4 MB

About the Author

Professor Peter Jenner is a specialist in preclinical aspects of neurodegenerative diseases, notably Parkinson’s disease. He has spent the major part of his career at King’s College London where he was Head of Pharmacology for 14 years before returning to his research roots and subsequently becoming Emeritus Professor of Pharmacology. Peter has expertise in drug metabolism and pharmacokinetics but neuropharmacology based on functional models of neurodegenerative diseases has formed the major focus of his work. Peter holds a BPharm, PhD and DSc degree from the University of London. He has published well over 1000 articles with more than 700 peer reviewed papers. He is a Fellow of the Royal Pharmaceutical Society, the British Pharmacological Society, the Royal Society of Medicine and of King’s College London. Peter was recently honoured with a Doctor Honoris Causa degree from Carol Davila University of Medicine and Pharmacy, Bucharest and made an Honorary Fellow of The British Pharmacological Society for his contribution to research in to movement disorders.

Peter has worked closely with the pharmaceutical industry for many years and acts as an adviser and consultant to both major pharma and biotech companies. He has a wide knowledge of the drug discovery and drug development process and has been involved from molecule synthesis through to drug registration for use in man. Peter was the Founder, Director and Chief Scientific Officer of Proximagen, a biotech focussed on the treatment and cure of neurodegenerative diseases that was listed on AIMs and subsequently purchased by a US based healthcare company. He is a regular speaker at international meetings and also takes time to speak at Parkinson’s disease patient-carer groups across the UK.

Table of Contents

Basic Science:
B.E. Leonard, The Pharmacology of the Phenothiazines, Butyrophenones, Thioxanthines, and Diphenylbutylpiperidines.
D.M. Coward, The Pharmacology of Clozapine-Like Atypical Antipsychotics.
J. Gerlach, Pharmacology and Clinical Properties of Selective Dopamine Antagonists, with Focus on Substituted Benzamides.
J.L. Waddington, Pre- and Postsynaptic D-1 to D-5 Dopamine Receptor Mechanisms in Relation to Antipsychotic Activity.
N.J. Rupniak and S.D. Iversen, Prediction of Antipsychotic Activity.
P.J. Harrison, Effects of Neuroleptics on Neuronal and Synaptic Structure.
P.F. Liddle, Brain Imaging and Antipsychotic Drugs.
S.H. Curry, Pharmacokinetics of Antipsychotic Drugs.
Clinical Issues:
S.R. Hirsch, The Assessment of Antipsychotic Activity in Clinical Trials.
R.G. McCreadie, Indications of Antipsychotic Drugs.
J.M. Kane, Acute Treatment.
J.M. Davis, P.G. Janicak, A. Singla, and R.P. Sharma, Maintenance Treatment.
D.A.W. Johnson, Depot Neuroleptics.
T.R.E. Barnes and J.G. Edwards, The Side Effects of Antipsychotic Drugs I: Neuropsychiatric Effects.
J.G. Edwards and T.R.E. Barnes, The Side Effects of Antipsychotic Drugs II: Effects on Other Physiological Systems.